
Cardiology
Latest News
Video Series

Latest Videos
Shorts










Podcasts
CME Content
More News

Robert Rosenson, MD, discusses the long-term extension of the phase 3 PALISADE trial, which demonstrated plozasiran’s association with lower ApoC3 and fasting TG.

Sachdev explains how VasCog-2-WSO criteria integrate new MRI markers, biomarkers, and unified terminology for vascular dementia.

Behnood Bikdeli, MD, MS, discusses his long-term follow-up to the HI-PRO study, which noted apixaban’s lasting effects on venous thromboembolism.

Ryan Tedford, MD, discusses his analysis of the phase 2 CADENCE trial, highlighting sotatercept’s beneficial effects on both the right and left sides of the heart.

Kausik Ray, MD, MBChB, MPhil, discusses Lp(a)HORIZON, remnant cholesterol targets, enlicitide, and the lipid outcome trials to watch in 2027.

In 757 adults with severe hypertriglyceridemia, plozasiran cut acute pancreatitis events by 78% overall and 91% in those with recent prior pancreatitis.

Todd Villines, MD, discusses the PARAMOUNT trial, which contrasted AI-based CT scan analysis against standard-of-care in patients with suspected CAD.

Gregory Piazza, MD, MS, discusses the results of ROXI-CATH, which illustrated amrecibart’s and cenvacibart’s efficacy in reducing thrombosis events without increasing bleeding.

With LDL-C target-guided titration, starting statin plus ezetimibe vs a statin alone yielded similar 3-year events in ASCVD.

Stopping statins was noninferior at 2 years in adults 70 and older without CVD, but events were higher over full follow-up (12.7% vs 9.2%).

Asundexian lowered ischemic stroke without more major bleeding across low, intermediate, and high Framingham risk groups (all P interaction > .25).

Adding spironolactone lowered 3-month home SBP by 7.7 mm Hg vs standard care in 160 stroke survivors with uncontrolled hypertension.

A systolic target below 120 mm Hg lowered major cardiovascular events vs below 140 mm Hg in 4368 patients with prior ischemic stroke or TIA.

































































